{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"No ADA formation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"ADAs formation to LMB-100 were measured by the enzyme-linked immunosorbent assay (ELISA). The presence of ADAs (i.e., positive) may indicate the participant may have poor blood levels.","groups":[{"description":"Dose Level 1: 170mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG000","title":"Dose Level 1: 170mcg LMB-100"},{"description":"Dose Level -1: 140mcg LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles.","id":"OG001","title":"Dose Level -1: 140mcg LMB-100"},{"description":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel given intravenously. LMB-100 given intravenously on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles. Nab-Paclitaxel given intravenously on days 1 and 8 of each 21 day cycle for up to 6 cycles.","id":"OG002","title":"Dose Level -2: 100mcg LMB-100 + Nab-Paclitaxel"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 2 (each cycle is 21 days), approximately 42 days","title":"Number of Participants With Anti-drug Antibodies (ADAs) Formation to LMB-100","type":"SECONDARY","unitOfMeasure":"Participants"}